AbbVie Inc. (BCBA:ABBV)

Argentina flag Argentina · Delayed Price · Currency is ARS
34,220
-260 (-0.75%)
At close: Dec 5, 2025
75.26%
Market Cap 576.58T
Revenue (ttm) 81.74T
Net Income (ttm) 3.22T
Shares Out n/a
EPS (ttm) 1,809.89
PE Ratio 179.18
Forward PE 16.52
Dividend 502.66 (1.47%)
Ex-Dividend Date Oct 15, 2025
Volume 499
Average Volume 1,697
Open 34,500
Previous Close 34,480
Day's Range 33,880 - 34,520
52-Week Range 18,475 - 38,540
Beta n/a
RSI 49.98
Earnings Date Jan 30, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange Buenos Aires Stock Exchange
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.